Diagnosis of recurrent bladder cancer by fluorescence in situ hybridization assay on urine sediment cells
A sample of 63 patients with bladder cancer (BC) was used to estimate the informative value of a noninvasive UroVysion test carried out prior to cystoscopy on urine sediment cells when diagnosing BC recurrences. The latter were detected by either the two techniques (cystoscopy and fluorescence in situ hybridization (FISH) assay) or one of them in 19 patients in different periods after treatment for primary BC (1-36 months). Cystoscopy revealed 13 recurrent BC cases; FISH assay identified 17 cases and in earlier periods. The total sensitivity of the FISH assay was 84.6%. The sample of 20 FISH-positive primary patients showed a direct correlation between BC stage, grade, and the number of abnormal cells (as indicated the UroVysion test) in the urine sediment.